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Non aqua non igni locis pluribus utimur quam amicitia. 
Cicerone, Marco Tullio (106-43 a.C.) (De amicitia: VI, 32)
Coronary angiography (CA) and percutaneous coronary 
intervention (PCI) are an essential part of the standard 
management of patients with stable coronary artery 
disease (SCAD) and acute coronary syndrome (ACS). 
Improvements in PCI materials and techniques led over 
the years to the opportunity to treat coronary diseases of 
increasing anatomical complexity (1), at the cost of longer 
procedural times and larger doses of iodinated contrast 
media (ICM) to be used chasing optimal results (2). ICM 
carry a risk of contrast-induced acute kidney injury (CI-
AKI) and such iatrogenic complication represents the 
third cause of acute renal failure in hospitalized patients, 
after renal hypoperfusion and medications (3). Although 
the pathophysiological mechanism of this association 
has not been completely clarified, both a direct ICM 
toxicity and indirect effects (i.e., viscosity-mediated renal 
vasoconstriction leading to medullary hypoxia) have been 
implicated (4,5). CI-AKI has been historically defined as 
the increase in the plasma creatinine level of at least 0.5 mg 
per deciliter or at least 25% increase from the baseline level 
within 2 to 5 days after exposure to contrast material (6). 
This led to large disputes about the correctness of such 
a definition in consideration of the low sensitivity of 
creatinine as an indicator of kidney function by itself. 
Despite in most cases such condition is reversible and the 
estimated glomerular filtration rate (eGFR) recovers in 
5 to 10 days (7) many studies have shown that CI-AKI, 
even defined as small decrements in renal function, is 
associated with long term higher rates of cardiovascular 
events, heart failure, and requirement for dialysis (8,9). The 
acknowledgment that CI-AKI is associated with adverse 
outcomes substantially led to two consequences. First, the 
fear among physicians about ICM-mediated kidney damage 
resulted in an increasing withholding of contrast-based 
procedures from patients suffering from chronic kidney 
disease (the exaggerated consequence of such phenomenon 
being referred to as “renalism” by Chertow et al. (10). 
This also represents a source of a potential indication 
bias of all the studies investigating this subject, as patients 
perceived at “higher risk” are less likely to be exposed to 
contrast material than are patients perceived at “lower-
risk”. On the other hand, several risk scores were developed 
with the aim to predict such complication (11,12). In this 
issue of the Journal of Thoracic Disease, Ni et al. presented 
a new simple risk score with a good predictive ability on 
CI-AKI and severe short and long term outcomes as in-
hospital mortality and three years death and major adverse 
cardiovascular events (MACE) in patients scheduled for 
CA (13). The authors retrospectively analyzed the data 
from 3,469 consecutive patients undergoing CA and that 
were randomly assigned to a development dataset (n=2,313) 
and a validation dataset (n=1,156). They first evaluated 
several variables associated with CI-AKI using univariable 
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logistic regression analysis and then performed a stepwise 
multivariable logistic regression analysis to identify 
independent predictors of contrast-induced nephropathy 
(CIN). After multivariable adjustments, the authors 
identified 5 variables related to CIN, namely hypotension, 
congestive heart failure (CHF), age >5 years, acute 
myocardial infarction (AMI) and serum creatinine (sCR) 
≥1.5 mg/dL. A weighted integer coefficient value based 
upon beta value was assigned to these variables. Therefore, 
a risk score model was constructed where the final risk score 
for each patient represented the sum of integer coefficients. 
The risk score was validated throughout the validation 
cohort showing good predictive ability on CIN (c statistic 
0.829), in-hospital mortality (c statistic 0.909) and long-
term adverse outcomes (c statistic for three years MACE 
0.730). Of interest, the authors compared the predictive 
ability of their score with two pre-existing and validated 
scores, namely the Mehran (11) and the ACEF (12) risk 
scores showing similar accuracy in predicting short and long 
adverse outcomes. Despite the study has its major limitation 
in the retrospective and “single-center” design, the authors 
should be congratulated for the effort to confirm the 
relationship between several simple anamnestic variables 
and the incidence of CIN. The benefit of a risk model 
including only pre-procedural data is self-evident, and on 
the other hand, represents the most important limitation of 
the widely adopted Mehran risk score that instead accounts 
also for the impact of post-procedural variables as the 
volume of contrast administered and the use of intra-aortic 
balloon pump. The age, creatinine and ejection fraction 
(ACEF) (12) risk score mentioned by the authors shares 
the advantage of considering only three simple clinical 
variables to predict worse outcomes. However, it should be 
acknowledged that it was first designed as a mortality risk 
score for patients undergoing elective cardiac surgery (14) 
and was only later validated by Andò et al. (12) as a model to 
predict AKI among patients with ST-elevation myocardial 
infarction treated with primary PCI. 
As stated above, the variables identified by Ni et al. as 
independently related to CIN are well-recognized patient-
related risk factors for such complications. Several previous 
studies showed that pre-existing CKD represents the most 
significant risk feature and that the increase in risk is likely to 
continue with the decline in eGFR (15). In this context, the 
choice of the Authors to put a dichotomic value of sCR in 
their risk model could be considered as debatable. However, 
continuous variables as eGFR have a rather complex grading 
system with several categories and would require calculation 
using a computer. The choice of authors can be then 
justified as a pursuit of simplification. The role of AMI as 
a predictor of CIN could be easily perceived in a simplistic 
manner, as patients with ACS are more likely to undergo 
complex revascularization procedures requiring a larger 
amount of contrast media. However, Reinstadler et al. (16) 
found a significant association between microvascular injury 
and onset of AKI in a cohort of patients undergoing cardiac 
MR following STEMI, while there was no influence of 
contrast media. This data highlights the potential role of 
a cardio-renal “cross-talk” in the context of ACS and that 
hemodynamic instability represents a risk-factor per-se. For 
the same reason, the impact of CHF and hypotension can 
be easily understood in the light of the renal hypoperfusion 
frequently associated with such conditions. This would 
open a “marginal” discussion about the real impact of the 
currently adopted prevention strategy of volume expansion 
to prevent CI-AKI. Even if this consideration goes beyond 
the scope of this commentary paper, it would be an 
interesting matter of research to understand if isotonic fluid 
administration before CA just helps the kidney to “washout” 
the contrast media or could play a nobler role in correcting 
hypotension. A surprising finding of the paper by Ni and 
co-authors is instead the apparently uninfluential impact of 
diabetes on the risk of CIN. Although diabetes is commonly 
cited as a risk factor and included in other predictive models 
of CI-AKI (11), two aged studies suggested that it does 
not increase the risk of CIN among patients with normal 
kidney function (17,18). In particular, in accordance with 
the results of Ni et al. data from the Iohexol Cooperative 
Study showed that diabetes was not an independent risk 
factor but rather amplified susceptibility only in patients 
with underlying chronic kidney disease (18).
Further than confirming the impact of several baseline 
features on the risk of CIN, the work of Ni et al. allows 
us to speculate on several themes. CIN is one of the best 
examples of the modern era of Medicine where for a 
potentially severe complication or disease we have “more 
ways to predict, than ways to prevent”. We daily face with 
a myriad of papers suggesting scores with a variable level of 
complexity referred to this or that subset of patients, none 
prevailing on each other because of the several contexts of 
development and validation. Quite the reverse, strategies to 
prevent the diseases “predicted” are often no more than a 
handful or sometimes, paradoxically even no one. In hence, 
among many pre-treatments suggested across the years 
to prevent kidney damage from ICM, only isotonic NaCl 
solution resisted to the benchmark of the evidence-based 
2677Journal of Thoracic Disease, Vol 11, No 7 July 2019
© Journal of Thoracic Disease. All rights reserved. J Thorac Dis 2019;11(7):2675-2679 | http://dx.doi.org/10.21037/jtd.2019.06.51
medicine. In the recent large prospective PRESERVE 
trial, 5,177 patients at risk for renal complications (median 
eGFR, 50 mL/min/1.73m²) were randomly assigned to 
receive intravenous NaCl or sodium bicarbonate solution, 
and oral N-acetylcysteine or placebo, in a 2×2 factorial 
design (19). In this well-conducted and sufficiently powered 
clinical trial using a relevant primary outcome of major 
adverse kidney events (MAKE), i.e., a composite end-point 
including death, dialysis or a persistent decline in GFR at 90 
days, there was no benefit of sodium bicarbonate over NaCl 
or of N-acetylcysteine over placebo. Trials investigating 
a potential preventive role of other medications, i.e., 
statins, led to controversial results and were mostly limited 
by methodological biases (heterogeneous populations, 
small sample size, rate and dosages of administrations). 
Additional non-pharmacological technique as ischemic pre-
conditioning showed renal benefit before ICM-exposition 
for CA (20), but further studies are warranted to confirm 
the value of such method. The striking results of the 
PRESERVE trial could lead to a provocative question: 
why don’t we just give intravenous water to every patient 
committed for ICM administration? The answer to such 
a “simplistic” solution comes from another landmark 
trial facing this topic. The AMACING trial (21), which 
randomly assigned 660 patients undergoing contrast-
enhanced procedures to receive either peri-procedural 
intravenous isotonic saline or no intravenous fluids, there 
was no significant difference in the incidence of acute kidney 
injury between the hydration group and the no-hydration 
group. On the opposite, a higher rate of symptomatic heart 
failure was recorded in patients receiving prophylactic 
hydration, thus highlighting that in subjects with well-
preserved renal function and normal hydration status, the 
benefit of preventive hydration should be weighed against 
any potential risk in a perfectly patient-tailored approach.
Another concern raising from the paper by Ni et al. is that 
recently the role of CI-AKI as a causal factor of worse long-
term poor outcomes was questioned. Lassnigg et al., showed 
that both small postsurgical elevations and small decrements 
in plasma creatinine levels (≤0.5 mg per deciliter) 
were associated with increased 30-day mortality (22). 
A meta-analysis by Coca et al. (23), revealed that preventive 
interventions that reduced the incidence of AKI, failed to 
reduce the risk of long-term downstream adverse events as 
death or development of CKD. These findings pointed out 
some doubts about a direct cause-effect correlation between 
CI-AKI and adverse outcomes. The adverse prognosis may 
be probably related to risk factors increasing risk of CI-AKI 
which are negatively related also to long term outcomes.
In light of all these considerations, we should ask 
ourselves if we really needed another score to predict 
ICM-mediated kidney injury. However, the present score 
should be of help to remember us single and easy to assess 
variables which are related to CI-AKI. Currently, data 
keep on showing a relationship between CI-AKI and poor 
outcomes. The recent POSEIDON trial (24) reported 
an overall incidence of CI-AKI of 11.4% and notably 
these patients had a higher rate of all-cause mortality and 
myocardial infarction at six months. Actually, it is difficult 
to establish if this relation is merely associational and if CI-
AKI is a real mediator of adverse prognosis or no more than 
a marker of increased risk. However, it is undeniable that 
CI-AKI appears to be more than just a “creatinopathy”. Liu 
et al. highlighted that all existing scores (including Mheran 
and ACEF), while performing well for CIN prediction, they 
all had low predictive accuracy for three years MACE (25). 
The work of Ni et al. deserves the merit to suggest a risk 
model with a remarkable predictable power not only on 
CIN but also on long-term major adverse outcomes. In our 
opinion, the future challenge will be to identify predictors 
able to discriminate between patients experiencing “real” 
ICM-mediated kidney damage, likely to be associated with 
a bad prognosis, and patients in whom we just observe 
fluctuation in plasma creatinine of uncertain significance. 
This would be of pivotal clinical relevance to avoid an 
exaggerated and unjustified “renalist” approach and, on the 
other hand, to properly select patients deserving specific 
preventive strategies and a stricter follow-up. The work 
of Ni and co-authors goes in this direction as the score 
suggested can be considered as a good-friend for physician 
who cares for patients at risk of CIN, and as in the famous 
citation of Cicerone, a friend sometimes is more useful than 
water. 
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